Breast neoplasms Trials in New York, United States
Conditions / Breast neoplasms / New York, United States
Research into Breast neoplasms spans multiple therapeutic approaches and trial phases.
52 total trials for this combination
Showing top 10 of 52 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06234488 | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | ACTIVE_NOT_RECRUITING | — |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | COMPLETED | PHASE1 |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | RECRUITING | PHASE2 |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | RECRUITING | — |
| NCT04711109 | Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00191152 | A Phase III Trial For Patients With Metastatic Breast Cancer | COMPLETED | PHASE3 |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | RECRUITING | — |
| NCT00051779 | An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer | COMPLETED | PHASE1 |
| NCT03678883 | 9-ING-41 in Patients with Advanced Cancers | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | RECRUITING | — |